

P&T Motion History

Proprotein Convertase Subtilisin Kexin type 9 (PCSK9) Inhibitors

Drugs Reviewed	Motion	Date Reviewed	Scan Accepted as Adequate	Reiteration of Prior Motion	Decision
alirocumab evolocumab	<p>After considering the evidence of safety, efficacy and special populations for the treatment of hypercholesterolemia, I move that alirocumab and evolocumab are safe and efficacious for the treatment of their approved indications. PCSK9 Inhibitors can be subject to therapeutic interchange in the Washington preferred drug list.</p> <p>Motion: Wisner 2nd: Harvey</p>	October 16, 2019	NA	Schwilke Storhaug	Passed unanimous